Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;12(6):593-602.
doi: 10.1586/erm.12.59.

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing

Frank S Ong  1 , Kingshuk Das, Jay Wang, Hana Vakil, Jane Z Kuo, Wendell-Lamar B Blackwell, Stephen W Lim, Mark O Goodarzi, Kenneth E Bernstein, Jerome I Rotter, Wayne W Grody
Affiliations
Review

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing

Frank S Ong et al. Expert Rev Mol Diagn. 2012 Jul.

Abstract

In the field of oncology, clinical molecular diagnostics and biomarker discoveries are constantly advancing as the intricate molecular mechanisms that transform a normal cell into an aberrant state in concert with the dysregulation of alternative complementary pathways are increasingly understood. Progress in biomarker technology, coupled with the companion clinical diagnostic laboratory tests, continue to advance this field, where individualized and customized treatment appropriate for each individual patient define the standard of care. Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.

PubMed Disclaimer

References

    1. August J. Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov. 2010;9(5):351. - PubMed
    1. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352–364. - PubMed
    1. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–1823. - PubMed
    1. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, De Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011;11(2):171–182. - PubMed
    1. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004;10(11):3885–3896. - PubMed

Websites

    1. ClinicalTrials.gov. An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT01194050.
    1. ClinicalTrials.gov. OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT00036647.

Publication types